RecruitingPhase 2NCT04765137

Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)

Targeting Cerebrovascular Reactivity for Precision Medicine: Pilot Trial of Atorvastatin

Sponsor

Johns Hopkins University

Enrollment

20 participants

Start Date

May 21, 2021

Study Type

INTERVENTIONAL

Conditions

Mild Cognitive Impairment

Summary

The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.

Eligibility

Min Age: 60 YearsMax Age: 95 Years

Inclusion Criteria5

MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.
Not demented by history.
Not taking statins currently or in the last 6 months.
Cognitive/functional impairment not likely due to another neurological disease or delirium.

Exclusion Criteria8

Taking a statin currently or have taken a statin in the last 6 months.
Contraindications to taking a statin.
Transplant patient taking cyclosporine.
Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
Diagnosis of dementia by history.
Current diagnosis of substance abuse.
History of stroke or myocardial infarction in past 6 months.
History of HIV.